摘要
目的:探讨结肠直肠癌(CRC)对一线化疗(卡培他滨联合奥沙利铂(XELOX))的耐药机制,确定了两个假定的耐药microRNAs,mir-1914 * 和- 1915,其降低血浆标本与化疗耐药的结肠直肠癌患者。 方法:一些从大肠癌患者的血浆样本进行分析的mir-1914 *水平和1915。对人结肠癌细胞株耐药2种小分子RNA稳定表达的影响进行了分析。肿瘤的形成和在HCT116/5-Fu/OXA 耐药表达或不表达在小鼠内进行分析的两种microRNAs。核因子I / X(nfix)被预测以2个miRNA的基因为目标并在体内和体外得到验证。 结果:血浆miR-1914* 和- 1915水平在化疗耐药的结直肠癌患者有不同程度的反应,并与临床反应相关。过度的mir-1914 * - 1915在化疗耐药的结肠癌细胞降低体外对5-氟尿嘧啶和奥沙利铂的耐药性。miRNA在CRC肿瘤小鼠影响细胞的生长、侵袭、凋亡和肿瘤抑制功能抑制耐药。mir-1914 * 和- 1915与3’---非翻译区NFIX相互作用并且降低NFIX在CRC细胞的水平的化学疗法。过过度的nfix没有抑制耐药结肠癌细胞活力和耐药蛋白在mir-1914 *和 - 1915转染的时候。 结论:血浆mir-1914 * 和- 1915与NFIX RNA相互作用同时减少耐药结肠癌细胞水平的一线化疗。miR-1914*和-1915的正向调节降低化学疗法的结直肠癌细胞的耐药能力。血浆mir-1914 * 和-1915可能在结直肠癌治疗和诊断中发挥作用。
关键词: 结肠直肠癌,化疗耐药,非编码核糖核酸,血浆。
Current Molecular Medicine
Title:The Plasma microRNA miR-1914* and -1915 Suppresses Chemoresistant in Colorectal Cancer Patients by Down-regulating NFIX.
Volume: 16 Issue: 1
Author(s): J. Hu, G. Cai, Y. Xu and S. Cai
Affiliation:
关键词: 结肠直肠癌,化疗耐药,非编码核糖核酸,血浆。
摘要: Objective: We investigated mechanisms of colorectal cancer (CRC) chemoresistance to first-line chemotherapy (capecitabine plus oxaliplatin (XELOX)) and identified two putative chemoresistant microRNAs, miR-1914* and -1915, that are downregulated in plasma samples from patients with chemoresistant CRC.
Methods: A number of plasma samples from CRC patients were analyzed for the levels of miR-1914* and - 1915. Effects of stable and transient expression of 2 microRNAs in human chemoresistant CRC cell lines were analyzed. Tumor formation and chemoresistance in HCT116/5-Fu/OXA that did or did not express 2 microRNAs were analyzed in mice. Nuclear factor I/X (NFIX) was predicted to target the gene of 2 miRNAs and verified in vivo and in vitro.
Results: Plasma levels of miR-1914* and -1915 in chemoresistant CRC patients were different than levels in responders, and associated with clinical response. Overexpression of miR-1914* and -1915 in chemoresistant CRC cells reduced resistance to 5-FU and Oxaliplatin in vitro. The microRNAs suppressed chemoresistance in CRC tumors in mice by affecting cell growth, invasion, apoptosis and tumor suppressor function. miR-1914* and -1915 interacted with the 3’-untranslated region of NFIX and reduced NFIX its level in chemoresistant CRC cells. Overexpression of NFIX did not inhibit chemoresistant CRC cell motility and chemoresistant proteins when miR-1914* and -1915 were transfected.
Conclusion: Plasma miR-1914* and -1915 interact with NFIX RNA and reduce its level in chemoresistant CRC cells to first-line chemotherapy. Up-regulation of miR-1914* and -1915 decreased the chemoresistance abilities of chemoresistant CRC cells. The plasma miR-1914* and -1915 may play a role in colorectal cancer therapy and diagnosis.
Export Options
About this article
Cite this article as:
J. Hu, G. Cai, Y. Xu and S. Cai , The Plasma microRNA miR-1914* and -1915 Suppresses Chemoresistant in Colorectal Cancer Patients by Down-regulating NFIX., Current Molecular Medicine 2016; 16 (1) . https://dx.doi.org/10.2174/1566524016666151222144656
DOI https://dx.doi.org/10.2174/1566524016666151222144656 |
Print ISSN 1566-5240 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5666 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Polymer-Drug Nanoconjugate – An Innovative Nanomedicine: Challenges and Recent Advancements in Rational Formulation Design for Effective Delivery of Poorly Soluble Drugs
Pharmaceutical Nanotechnology Epigenetics of Aging
Current Genomics 4-aryl/heteroaryl-4H-fused Pyrans as Anti-proliferative Agents: Design, Synthesis and Biological Evaluation
Anti-Cancer Agents in Medicinal Chemistry Label-Free Cell Phenotypic Assays for Assessing Drug Polypharmacology
Current Pharmaceutical Design Aurora B Kinase and Passenger Proteins as Targets for Cancer Therapy
Current Enzyme Inhibition Insights into Targeting Colon Cancer Cell Fate at the Level of Proteoglycans / Glycosaminoglycans
Current Medicinal Chemistry Phage Display Derived Therapeutic Antibodies
Current Pharmaceutical Biotechnology Recent Patents Reveal Microtubules as Persistent Promising Target for Novel Drug Development for Cancers
Recent Patents on Anti-Infective Drug Discovery Multiple Functions of Generic Drugs: Future Perspectives of Aureolic Acid Group of Anti-Cancer Antibiotics and Non-Steroidal Anti-Inflammatory Drugs
Mini-Reviews in Medicinal Chemistry Taming Oncogenic Signaling at Protein Interfaces: Challenges and Opportunities
Current Topics in Medicinal Chemistry High Throughput Genetic Screening for the Detection of Hereditary Nonpolyposis Colon Cancer (HNPCC) Using Capillary Electrophoresis
Combinatorial Chemistry & High Throughput Screening MYC-Mediated Synthetic Lethality for Treating Tumors
Current Cancer Drug Targets Dasatinib: An Anti-Tumour Agent via Src Inhibition
Current Drug Targets An Emerging Molecular Target in Melanoma: Cellular Carbonyl Stress and the Inhibition of Mitochondrial Survival Pathways by Carbonyl Scavenger Agents
Current Cancer Therapy Reviews Lycopene Modulation of Molecular Targets Affected by Smoking Exposure
Current Cancer Drug Targets From the Table to the Bedside: Can Food-Derived Sulforaphane be used as a Novel Agent to Treat Leukemia?
Current Cancer Drug Targets The Cross-over of Anticancer Agents with Osteoclast Activities
Current Cancer Therapy Reviews Extracellular Vesicles as Novel Delivery Tools for Cancer Treatment
Current Cancer Drug Targets Molecular Mistletoe Therapy: Friend or Foe in Established Anti-Tumor Protocols? A Multicenter, Controlled, Retrospective Pharmaco-Epidemiological Study in Pancreas Cancer
Current Molecular Medicine Tailored Angiogenesis Inhibition in Cancer Therapy: Respecting the Heart to Improve the Net Outcome
Current Signal Transduction Therapy